Previse is a pioneering company in the field of precision medicine, focusing on the prevention and early detection of cancer, starting with esophageal cancer. Utilizing proprietary epigenetic biomarkers and advanced data science, Previse offers innovative solutions that support diverse clinical study populations globally. The company's core product, Esopredict TM, is a molecular test that provides personalized guidance for esophagus surveillance and treatment decisions. This test, along with the Esoscore TM report, helps healthcare providers and patients understand the future risk of progression from esophagus to esophageal cancer and the necessary steps for treatment. Previse operates in the healthcare sector, primarily serving healthcare providers and patients who are at risk of esophageal cancer. The business model revolves around offering specialized diagnostic tests that are available through licensed healthcare providers, generating revenue through the sale of these tests. By focusing on early detection and prevention, Previse aims to reduce the incidence and mortality rates associated with esophageal cancer.

Keywords: precision medicine, early detection, cancer prevention, epigenetic biomarkers, data science, esophageal cancer, molecular test, healthcare providers, diagnostic tests, personalized guidance.